Cargando…

PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant

Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). Clinical response to ASCT has been associated with DNA repair efficiency. Here we interrogated the role of the base excision DNA repair (BER) pathway in MM response to ASCT. Across 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Melissa, Li, Junan, King, Kevan, Persaud, Avinash K., Duah, Ernest, Vangundy, Zachary, Hofmeister, Craig C., Lamba, Jatinder K., Tan, Aik Choon, Fridley, Brooke L., Poi, Ming J., Seligson, Nathan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Article - Multiple Myeloma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388271/ https://www.ncbi.nlm.nih.gov/pubmed/36861411 http://dx.doi.org/10.3324/haematol.2022.282399

Ejemplares similares

The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018)

MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology Center
por: Sahakyan, Lusine, et al.
Publicado: (2021)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
por: Byun, Ja Min, et al.
Publicado: (2020)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

Case series: MRD negativity assessment using (11)C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
por: Ngai, Cheong, et al.
Publicado: (2021)

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
por: Usmani, Saad Z., et al.
Publicado: (2022)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation
por: Yang, Chen-lu, et al.
Publicado: (2021)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis
por: Li, Guang, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019)

Bone marrow niche in multiple myeloma and its precursor states
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2019)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma
por: Chavez, Julio C., et al.
Publicado: (2022)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Prognostic and clinicopathological impacts of systemic immune-inflammation index on patients with diffuse large B-cell lymphoma: a meta-analysis
por: Fan, Zaijing, et al.
Publicado: (2023)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Roles of human POLD1 and POLD3 in genome stability
por: Tumini, Emanuela, et al.
Publicado: (2016)

Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease
por: Pierson, Sheila K, et al.
Publicado: (2021)

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors
por: Chan, Wei Yee, et al.
Publicado: (2021)

A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway
por: Grytten, N, et al.
Publicado: (2016)

CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients
por: Ghandili, Susanne, et al.
Publicado: (2021)

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
por: Branagan, Andrew R., et al.
Publicado: (2021)

Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study
por: Fillmore, Nathanael R, et al.
Publicado: (2021)

Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients
por: Stampfer, Samuel D., et al.
Publicado: (2021)

The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey
por: Redder, Louise, et al.
Publicado: (2021)

Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial
por: Jenner, Matthew W, et al.
Publicado: (2021)

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
por: Martínez-López, Joaquín, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ln6mjgm7e64pti4q147o9la1f6